Supernus Pharmaceuticals (SUPN) Gains from Investment Securities (2020 - 2026)

Supernus Pharmaceuticals has reported Gains from Investment Securities for 7 years, with the latest figure at $2.4 million in Q1 2026.

• Gains from Investment Securities for Q1 2026 came in at $2.4 million, down 68.79% year-over-year; the trailing twelve-month figure through Jun 2026 was $20.2 million (up 187.86% YoY), and the FY2025 annual result was $25.4 million, up 516.02% from the prior year.
• Gains from Investment Securities declined to $2.4 million in Q1 2026, from $17.8 million in the prior quarter.
• Over five years, Gains from Investment Securities peaked at $17.8 million in Q4 2025 and troughed at -$4.4 million in Q2 2024.
• A 5-year average of $1.3 million and a median of $356000.0 in 2024 frame the typical range for Gains from Investment Securities.
• The widest annual swing landed in 2024, when Gains from Investment Securities plunged 651.27%; it then jumped 4888.48% in 2025.
• A 5-year view of Gains from Investment Securities shows it stood at -$2.4 million in 2022, then soared by 91.51% to -$204000.0 in 2023, then soared by 274.51% to $356000.0 in 2024, then jumped by 4888.48% to $17.8 million in 2025, then plunged by 86.54% to $2.4 million in 2026.
• Per Business Quant data, the three most recent Gains from Investment Securities figures were $2.4 million in Q1 2026, $17.8 million in Q4 2025, and $7.7 million in Q1 2025.